NEW YORK (GenomeWeb) – Pacific Biosciences announced today that it has priced an underwritten public offering of 15.4 million shares of common stock at $3.10 per share.

PacBio has also granted the underwriters a 30-day option to purchase up to an additional 2.3 million shares. After deducting the underwriting discount and expenses, the company expects to raise net proceeds of approximately $45.9 million, assuming the underwriter's option to purchase additional shares is not exercised.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.